NASDAQ:DOVA Dova Pharmaceuticals (DOVA) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free DOVA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$28.04▼$28.0450-Day Range$28.04▼$28.0452-Week Range$5.62▼$28.54Volume35,036 shsAverage Volume499,313 shsMarket Capitalization$807.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Dova Pharmaceuticals alerts: Email Address Ad InvestorPlaceYour Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.Click to watch this device in action About Dova Pharmaceuticals Stock (NASDAQ:DOVA)Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.Read More Ad InvestorPlaceYour Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.Click to watch this device in action DOVA Stock News HeadlinesApril 25, 2024 | msn.comCumberland Valley School Board reinstates assembly featuring ’30 Rock’ star after special meetingMarch 7, 2024 | uk.finance.yahoo.comAnalysis of Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology Signed During 2016-2024May 13, 2024 | InvestorPlace (Ad)Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.August 22, 2023 | bizjournals.comFulcrum swings back up after FDA lifts clinical holdMay 15, 2023 | technews.tmcnet.comFulcrum Therapeutics Appoints Alex C. Sapir Chief Executive OfficerMarch 29, 2023 | marketwatch.comImmune Thrombocytopenia Market 2023 Size to reach USD 3.33 Billion by 2026 With A 0.54% CAGRMarch 21, 2023 | marketwatch.comWith A 0.54% CAGR, Immune Thrombocytopenia Market 2023 Size Will Reach USD 3.33 Billion by 2026February 27, 2023 | marketwatch.comLatest Research on Chemotherapy Induced Thrombocytopenia Drugs Market Report 2023-2029May 13, 2024 | InvestorPlace (Ad)Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.February 19, 2023 | marketwatch.comGlobal Immune Thrombocytopenia Treatment Market Size To Grow On The Basis Of Refined Innovation From 2023-2030 By VMReportsSeptember 20, 2022 | finance.yahoo.comPasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of DirectorsSeptember 14, 2022 | investing.comTethys Oil AB (TETY)August 11, 2022 | fool.comMolina Healthcare (NYSE: MOH)July 23, 2022 | uk.news.yahoo.comUK watchdog fines Pfizer, Flynn Pharma $84 million for overcharging NHSJuly 19, 2022 | marketwatch.comGlobal Immune Thrombocytopenia Market to Rise at 0.54% CAGR from 2019-2026June 9, 2022 | investing.comDOVA_old Historical DataApril 30, 2022 | uk.finance.yahoo.com'This is not pressure' - Passionate Parker issues rallying cry ahead of huge Blackburn clashApril 30, 2022 | reuters.comUkraine Holocaust survivors find shelter in IsraelMarch 24, 2022 | marketwatch.comImmune Thrombocytopenia (ITP) Market Research Update, Size Estimation, Future Scope, Revenue Opportunities and Regional Forecast to 2028November 9, 2021 | benzinga.comVerona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateSeptember 2, 2021 | marketwatch.comAdvent, GIC Affiliate Launch $8.1 Bln Takeover Bid for Sweden's SobiSee More Headlines Receive DOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dova Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2019Today5/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:DOVA CUSIPN/A CIK1685071 Webwww.dova.com Phone919-748-5975FaxN/AEmployees115Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,280,000.00 Net Margins-544.09% Pretax MarginN/A Return on Equity-101.60% Return on Assets-67.21% Debt Debt-to-Equity Ratio0.41 Current Ratio5.64 Quick Ratio5.37 Sales & Book Value Annual Sales$10.35 million Price / Sales78.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book10.35Miscellaneous Outstanding Shares28,800,000Free FloatN/AMarket Cap$807.55 million OptionableOptionable Beta2.74 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. David S. Zaccardelli (Age 54)Pres & CEO Mr. Mark W. Hahn (Age 56)CFO & Sec. Mr. Kevin Laliberte (Age 41)Sr. VP of Product Devel. Mr. Jason LevineVP of MarketingMr. Ilija ZlatarHead of U.S. SalesKey CompetitorsLongboard PharmaceuticalsNASDAQ:LBPHPliant TherapeuticsNASDAQ:PLRXSage TherapeuticsNASDAQ:SAGETango TherapeuticsNASDAQ:TNGXEvolusNASDAQ:EOLSView All Competitors DOVA Stock Analysis - Frequently Asked Questions How were Dova Pharmaceuticals' earnings last quarter? Dova Pharmaceuticals Inc (NASDAQ:DOVA) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The firm earned $3.52 million during the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative trailing twelve-month return on equity of 101.60%. What other stocks do shareholders of Dova Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Aldeyra Therapeutics (ALDX), Tesaro (TSRO), Allena Pharmaceuticals (ALNA), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Ardelyx (ARDX), Fate Therapeutics (FATE), Galectin Therapeutics (GALT) and Heron Therapeutics (HRTX). When did Dova Pharmaceuticals IPO? Dova Pharmaceuticals (DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO. This page (NASDAQ:DOVA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dova Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
